source
- Axiom Biosciences targets Hong Kong IPO to raise up to $200 million for regenerative therapy pipelineAxiom Biosciences, a San Diego‑based biotech, announced plans to list on the Hong Kong Stock Exchange rather than the traditional U.S. exchanges. The company aims to use the offering to secure new…
- Rare-disease biotech coalition urges Trump admin to carve out orphan drugs from Medicare price-cut pilotsBiotech firms formed the Rare Disease Company Coalition and met with the White House Office of Management and Budget to discuss excluding orphan drugs from two Medicare price‑cut pilot programs. T…